Abivax (ABVX) Non-Current Deferred Tax Liability (2023 - 2026)

Abivax's Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $6.8 million, up 297.06% from the prior year.
• Non-Current Deferred Tax Liability improved to $7.1 million in Q1 2026 per ABVX's latest filing, from $6.8 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $7.1 million in Q1 2026 and bottomed at $477717.3 in Q4 2023.
• The 4-year median for Non-Current Deferred Tax Liability is $4.2 million (2024), against an average of $4.0 million.
• Across the five-year window, Non-Current Deferred Tax Liability surged 254.32% in 2024 and surged 302.17% in 2025, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $477717.3 in 2023, then soared by 254.32% to $1.7 million in 2024, then jumped by 302.17% to $6.8 million in 2025, then increased by 4.5% to $7.1 million in 2026.
• Per Business Quant, the three latest ABVX Non-Current Deferred Tax Liability figures stand at $7.1 million (Q1 2026), $6.8 million (Q4 2025), and $1.7 million (Q4 2024).